Cancer Genetics, Inc.
|Number of Estimates|
Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.
Market Cap: 6.38 Million
Primary Exchange: NASDAQ
Shares Outstanding: 2.1 Million
Float: 1.85 Million
Sector: Health Technology
Industry: Medical Specialties
Longest drawdown: 1743 trading days
From: 2013-09-27 To: 2020-05-22
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|